BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
WALTHAM, Mass., Nov. 09, 2016 -- Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Tuesday, November 15, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2016.
| Tuesday, November 15th, 8:30 a.m. Eastern Time | ||
| Dial in (domestic): | 877-324-1976 | |
| Dial in (international): | 631-291-4550 | |
| Conference ID: | 13333032 | |
A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels. Interleukin Genetics’ lead products include its proprietary ILUSTRA™ Inflammation Management Program for periodontal disease and tooth loss susceptibility available through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA, and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Investor Contact: Steve DiPalma Interleukin Genetics, Inc. (508) 654-4572 [email protected] Media Contact: Jennifer Moritz Zer0 to 5ive for Interleukin Genetics (917) 748-4006 [email protected]
